157 related articles for article (PubMed ID: 7588428)
21. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
Farilla L; Bulotta A; Hirshberg B; Li Calzi S; Khoury N; Noushmehr H; Bertolotto C; Di Mario U; Harlan DM; Perfetti R
Endocrinology; 2003 Dec; 144(12):5149-58. PubMed ID: 12960095
[TBL] [Abstract][Full Text] [Related]
23. Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs.
Freyse EJ; Becher T; El-Hag O; Knospe S; Göke B; Fischer U
Diabetes; 1997 May; 46(5):824-8. PubMed ID: 9133550
[TBL] [Abstract][Full Text] [Related]
24. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets.
Fehmann HC; Hering BJ; Wolf MJ; Brandhorst H; Brandhorst D; Bretzel RG; Federlin K; Göke B
Pancreas; 1995 Aug; 11(2):196-200. PubMed ID: 7479679
[TBL] [Abstract][Full Text] [Related]
25. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.
Siegel EG; Scharf G; Gallwitz B; Mentlein R; Morys-Wortmann C; Fölsch UR; Schmidt WE
Eur J Clin Invest; 1999 Jul; 29(7):610-4. PubMed ID: 10411667
[TBL] [Abstract][Full Text] [Related]
27. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice.
Ahrén B
Am J Physiol Regul Integr Comp Physiol; 2004 Feb; 286(2):R269-72. PubMed ID: 14707011
[TBL] [Abstract][Full Text] [Related]
28. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.
Edwards CM; Todd JF; Mahmoudi M; Wang Z; Wang RM; Ghatei MA; Bloom SR
Diabetes; 1999 Jan; 48(1):86-93. PubMed ID: 9892226
[TBL] [Abstract][Full Text] [Related]
30. The structure-function relationship of GLP-1 related peptides in the endocrine function of the canine pancreas.
Ohneda A; Ohneda K; Ohneda M; Koizumi F; Ohashi S; Kawai K; Suzuki S
Tohoku J Exp Med; 1991 Nov; 165(3):209-21. PubMed ID: 1807008
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
[TBL] [Abstract][Full Text] [Related]
32. Glucose stimulates the expression and activities of nitric oxide synthases in incubated rat islets: an effect counteracted by GLP-1 through the cyclic AMP/PKA pathway.
Jimenez-Feltstrom J; Lundquist I; Salehi A
Cell Tissue Res; 2005 Feb; 319(2):221-30. PubMed ID: 15558323
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.
Luque MA; González N; Márquez L; Acitores A; Redondo A; Morales M; Valverde I; Villanueva-Peñacarrillo ML
J Endocrinol; 2002 Jun; 173(3):465-73. PubMed ID: 12065236
[TBL] [Abstract][Full Text] [Related]
34. GLP-1(7-36) amide stimulates insulin secretion in rat islets: studies on the mode of action.
Fridolf T; Ahrén B
Diabetes Res; 1991 Apr; 16(4):185-91. PubMed ID: 1802486
[TBL] [Abstract][Full Text] [Related]
35. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
36. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the glucose dependency of glucagon-like peptide-1 (7-37) and glyburide in vitro and in vivo.
Hargrove DM; Nardone NA; Persson LM; Andrews KM; Shepherd KL; Stevenson RW; Parker JC
Metabolism; 1996 Mar; 45(3):404-9. PubMed ID: 8606650
[TBL] [Abstract][Full Text] [Related]
38. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.
Ahrén B; Holst JJ; Mari A
Diabetes Care; 2003 Oct; 26(10):2860-4. PubMed ID: 14514592
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
Ahrén B; Hughes TE
Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
[TBL] [Abstract][Full Text] [Related]
40. Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development.
García-Flores M; Zueco JA; Alvarez E; Blázquez E
Eur J Biochem; 2001 Feb; 268(3):514-20. PubMed ID: 11168389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
